A robust primary liver cancer subtype related to prognosis and drug response based on a multiple combined classifying strategy

作者全名："Deng, Jielian; Lai, Guichuan; Zhang, Cong; Li, Kangjie; Zhu, Wenyan; Xie, Biao; Zhong, Xiaoni"

作者地址："[Deng, Jielian; Lai, Guichuan; Zhang, Cong; Li, Kangjie; Xie, Biao; Zhong, Xiaoni] Chongqing Med Univ, Sch Publ Hlth & Management, Dept Epidemiol & Hlth Stat, Chongqing, Peoples R China; [Zhu, Wenyan] Chongqing Med & Pharmaceut Coll, Chongqing Engn Res Ctr Pharmaceut Sci, Chongqing, Peoples R China; [Zhu, Wenyan] Chongqing Med Univ, Coll Pharm, Chongqing, Peoples R China; [Deng, Jielian; Zhu, Wenyan] Yidu Cloud Beijing Technol Co, Med Dept, Beijing, Peoples R China"

通信作者："Xie, B; Zhong, XN (通讯作者)，Chongqing Med Univ, Sch Publ Hlth & Management, Dept Epidemiol & Hlth Stat, Chongqing, Peoples R China.; Zhu, WY (通讯作者)，Chongqing Med & Pharmaceut Coll, Chongqing Engn Res Ctr Pharmaceut Sci, Chongqing, Peoples R China."

来源：HELIYON

ESI学科分类：　

WOS号：WOS:001181645200001

JCR分区：Q1

影响因子：3.4

年份：2024

卷号：10

期号：3

开始页：　

结束页：　

文献类型：Article

关键词：Prognostic markers; Cancer molecular markers; Cancer stem cells; Immune microenvironment; Genotyping; Combined classifying; Drug sensitivity

摘要："The recurrence or resistance to treatment of primary liver cancer (PLL) is significantly related to the heterogeneity present within the tumor. In this study, we integrated prognosis risk score, mRNAsi index, and immune characteristics clustering to classify patients. The four subtypes obtained from the combined classification are associated with PLC's prognosis and drug response. In these subtypes, we observed mRNAsiH_ICCA subtype, the intersection between high mRNAsi and immune characteristics clustering A, had the worst prognosis. Specifically, immune characteristics clustering B (ICC_B) had high drug sensitivity in most drugs regardless of the value of mRNAsi. On the other hand, patients with low mRNAsi responded better to ten drugs including KU-55933 and NU7441, while patients with high mRNAsi might benefit from drugs like Leflunomide. By matching the specific characteristics of each combined subtype with the drug-induced cell line expression profile, we identified a group of potential therapeutic drugs that might regulate the expression of disease signature genes. We developed a feasible multiple combined typing strategy, hoping to guide therapeutic selection and promote the development of precision medicine."

基金机构：National Natural Science Foundation of China [82204159]; Postdoctoral Fund project of Chongqing [cstc2021jcyj-bshX0220]

基金资助正文："This research was funded by (National Natural Science Foundation of China) , grant number (82204159) and by (Postdoctoral Fund project of Chongqing) , grant number (cstc2021jcyj-bshX0220) ."